The cellular response to diverse classes of stress inducers includes growth arrest and induction of apoptosis. Apoptosis is triggered through a controlled program that is associated with distinctive morphological changes including membrane blebbing, cytoplasmic and nuclear condensation, chromatin aggregation, and formation of apoptotic bodies (1) . The induction of apoptosis involves a cascade of initiator and effector caspases that are activated sequentially (2, 3) . Caspases, a family of cysteine proteases with aspartate substrate specificity, are present in cells as catalytically inactive zymogens (2) . Once activated, the effector caspases induce proteolytic cleavage of various cellular targets, including poly(ADP-ribose) polymerase (PARP) 1 (4) , DNA-dependent protein kinase, protein kinase C-␦ (2), and other substrates, ultimately leading to cell death.
One of the major caspase cascades is triggered by the release of mitochondrial apoptogenic protein, cytochrome c (cyto-c) (5, 6) . Cytosolic cyto-c binds to the CED-4 homolog Apaf-1 and induces caspase-9-dependent activation of caspase-3 (7) . Recent studies have identified another important regulator of apoptosis, Smac (second mitochondria-derived activator of caspase) or DIABLO, which is released from mitochondria into the cytosol during apoptosis (8, 9) and functions by eliminating inhibitory effects of inhibitor of apoptosis proteins on caspase-9 (9, 10). Our prior studies showed that 2ME2-induced apoptosis in MM cells involves release of both cyto-c and Smac (11) . However, the upstream signal that triggers the 2ME2-induced mitochondrial apoptotic pathways in MM cells is unclear.
A recent study has shown that stress-activated protein kinase (SAPK) or c-Jun NH 2 -terinal Kinase (JNK) mediates the release of cyto-c during apoptosis (12) . JNK has been linked to apoptosis (13) (14) (15) . Specifically, two serine residues (Ser 63 and Ser 73 ) in the amino-terminal transactivation domain of c-Jun are substrates for JNK (13, 14) , and previous studies have shown that stress stimuli (e.g. irradiation, tumor necrosis factor, sphingomyelinase, and UV light) activate JNK (13) (14) (15) . In the present study, we show that 2ME2-induced apoptosis in MM cells is, at least in part, mediated by JNK activation, and JNK-dependent release of Smac from mitochondria to cytosol. Our findings provide the first evidence for the requirement of JNK in triggering Smac-mediated apoptosis.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents-Human MM.1S MM cells (11) were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine. Mononuclear cells were isolated from a patient with MM (PCL cells) by Ficoll-Hypaque density gradient centrifugation and incubated with HB-7 (anti-CD38) MoAb-biotin-streptavidin and 2H4 (anti-CD45RA) MoAb-fluorescein isothiocyanate on ice. Tumor cells (96 ϩ 2% CD38 ϩ 45RA-) were isolated using an Epics C cell sorter (Coulter Electronics, Hialeah, FL), washed, and resuspended in regular growth medium. Cells were treated with 3 M of 2ME2, or 10 nM proteasome inhibitor PS-341, as described previously (11, 16) . Cells were also treated with 3 M 2ME2 in the presence or absence of JNK-specific inhibitor SP600125 (17) .
Apoptotic Assays-Dual fluorescence staining with DNA-binding fluorochrome Hoechst 33342 and propidium iodide was used to quantitate the percentage of apoptotic (propidium iodide-Hoechst 33342ϩ) cells by flow cytometry (The Vantage, BD Biosciences), as described previously (11) .
In Vitro Immune Complex Kinase Assays-In vitro immune complex c-Jun or ATF2 kinase assays were performed as described previously (18) .
Preparation of Cytosolic and Mitochondrial Extracts from MM.1S and MM Patient Cells-MM.1S
or patient MM cells were washed twice with phosphate-buffered saline, and the pellet was suspended in 3 volumes of ice-cold buffer A (20 mM HEPES, pH 7.5, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, and 10 g/ml leupeptin, aprotinin, and pepstatin A) containing 250 nM sucrose. The cells were homogenized using a Dounce homogenizer, and cytosolic or mitochondrial extracts were isolated as described previously (19) .
Western Blot Analysis-Proteins were separated from cell lysates by SDS-PAGE, transferred to nitrocellulose, and probed with anti-Smac (kindly provided by Dr. Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas), anti-cyto-c (Sigma), anti-Hsp60 (Stressgen), anti-phospho-specific JNK (New England Biolabs), as well as anti-PARP (Pharmingen), or anti-JNK and anti-SHP2 (Santa Cruz Biotechnology, Santa Cruz, CA) Abs. The blots were developed by enhanced chemiluminescence (ECL), using the manufacturer's protocol (Amersham Biosciences).
Transient Transfections-MM.1S cells were transiently transfected using "cell line Nucleofecto TM kit V," according to manufacturer's instructions (Amaxa Biosystems), with vector alone or DN-JNK and cotransfected with vector containing green fluorescence protein (GFP) alone. Following transfections, GFP-positive cells were selected by flow cytometry, treated with 2ME2 (3 M) and analyzed for cell viability as described above. Additionally, cytosolic extracts from these cells were also analyzed for the accumulation of Smac by Western blotting as described previously.
MTT (3-(4,5-Dimethylthiozol-2-yl)-2,5-diphenyltetrazolium Bromide) Assays-Cell viability was assessed by MTT (Chemicon International
Inc., Temecula, CA) assay (Roche Molecular Biochemicals), and trypan blue exclusion, as described previously (11) .
Analysis of Mitochondrial Membrane Potential (⌬⌿ m ) Dissipation-MM.1S cells were treated with 2ME2 in the presence or absence of JNK inhibitor (SP600125) for 12 h, harvested, and analyzed for mitochondrial membrane potential (⌬⌿ m ). 2ME2 or dexamethasone-treated MM cells were stained with lipophilic cationic dye CMXRos (Mitotracker Red) (Molecular Probes, Eugene, OR) in phosphate-buffered saline for 20 min at 37°C and analyzed by flow cytometry to assay for alterations in ⌬⌿ m .
RESULTS AND DISCUSSION
To examine whether 2ME2 induces apoptosis in the MM.1S MM cells, we performed flow cytometric analysis using propidium iodide and Hoechst staining. Treatment of cells with 3 M 2ME2 for 24 h significantly increased the percentage of apoptotic cells (51% Ϯ 3.6%, p Ͻ 0.005, n ϭ 3), as in our prior studies (11) . Previous studies have shown that activation of JNK plays an important role in apoptosis (14, 15) . To examine whether 2ME2 induces activation of JNK, MM.1S MM cells were exposed to 2ME2 for various time intervals, and JNK activity was analyzed by in vitro immune complex kinase assays using GST-Jun as a substrate. Analysis of anti-JNK immunoprecipitates demonstrated significant (8 -10-fold) increase in GST-Jun phosphorylation, indicating the activation of JNK (Fig. 1A, upper left panel) . Moreover, cotreatment of MM.1S cells with SP600125, a specific inhibitor of JNK (17), blocks 2ME2-induced JNK activity (Fig. 1A, upper left panel) . This activation of JNK in response to 2ME2 does not alter JNK protein levels (Fig. 1A , lower left panel). Increase in JNK activity was detectable as early as 1h after 2ME2 treatment and peaked at 12 h/24 h (Fig. 1A, upper right panel) . Our findings are in concert with those of Verheij et al. (15) , which demonstrate a role of JNK in ceramide-and tumor necrosis factor-␣-induced apoptosis. Moreover, coordinate regulation of JNKs, p38, and extracellular signal-regulated kinase (ERK) kinases facilitates apoptosis induced by withdrawal of growth factor, suggesting that activation of JNK may be essential for apoptosis (20) .
We next examined the mechanism whereby JNK mediates its apoptotic effects during 2ME2-induced apoptosis. Translocation of JNK from cytosol to the nucleus has been shown in response to osmotic stress (21) . Other studies showed that JNK translocates to mitochondria after genotoxic stress and inhibits the anti-apoptotic function of proteins belonging to Bcl2 family members (22, 23) , thereby allowing the release of mitochondrial apoptogenic proteins to cytosol and subsequent activation of caspase cascades. We next therefore determined whether 2ME2 induces translocation of JNK to mitochondria or nucleus in MM cells. Cytosolic, mitochondrial, and nuclear extracts from untreated and 2ME2-treated MM.1S cells were assayed for the JNK protein levels. As seen in Fig. 1B (upper panel) , 2ME2 significantly increases JNK protein level in mitochondrial 
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fraction (4 -5-fold, as assessed by densitometry). Purity of mitochondria was confirmed by reprobing the blots with an antibody against mitochondrial-specific Hsp60 protein (Fig. 1B, lower panel) . No increases in JNK protein levels in the nuclear fractions were detected in 2ME2-treated cells (data not shown). Together, these findings demonstrate that 2ME2-induced apoptosis is associated with both activation of JNK and its translocation to mitochondria. These results suggest a potential involvement of mitochondria during 2ME2-induced apoptosis in MM cells.
Mitochondria harbor two key modulators of apoptosis, cyto-c and Smac (second mitochondria-derived activator of caspase) or DIABLO, which are released from mitochondria into the cytosol during apoptosis (5, 6, 8, 9, 24) . The upstream signal(s) that triggers the release of these proteins from mitochondria to cytosol is unclear. A recent study showed that activated JNK is required for the cyto-c release and associated apoptosis (12) ; however, the influence of JNK signaling on the release of Smac is presently undefined. Given that 2ME2 activates JNK in MM cells and JNK translocates to mitochondria, we next assessed whether 2ME2-induces the release of Smac and whether 2ME2-activated JNK mediates the release of Smac. MM.1S cells were treated with 2ME2, in the presence or absence of JNK inhibitor SP600125; cytosolic extracts were prepared and subjected to immunoblot analyses with anti-Smac Ab. As seen in Fig. 1C (upper panel) , 2ME2 induces the release of Smac, as in our previous study (11) . Importantly, cotreatment with SP600125 significantly inhibits the release of Smac (Fig. 1C,  upper panel) . Reprobing the immunoblots with anti-SHP2 (as control) confirms equal protein loading (Fig. 1C, lower panel) . These findings demonstrate that 2ME2-induced JNK activation is required for the mitochondrial release of Smac. Examination of the effects of 2ME2 on the release of cyto-c, as well as requirement of JNK for the release of cyto-c, demonstrated similar results (Fig. 1D) . To further address this issue, we transiently transfected MM.1S cells with either dominant-negative mutant of JNK (pEBG-DN-JNK) or control vector; following treatment with 2ME2, cytosolic extracts were analyzed for accumulation of Smac in the cytosol. As seen in Fig. 1E (first  panel) , overexpression of DN-JNK abrogates the 2ME2-induced release of Smac from mitochondria to cytosol. To confirm the expression of endogenous JNK and exogenous DN-JNK (GST-DN-JNK), filters were reprobed with anti-JNK antibody (Fig. 1E, second panel) . Immunoblotting with phospho-specific JNK antibody showed a marked decrease in 2ME2-induced JNK activity in cells transfected with DN-JNK compared with empty vector (Fig. 1E, third panel) , which confirmed the function of DN-JNK. Immunoblotting with anti-GFP and anti-SHP2 Abs demonstrated equal transfection efficiency and protein load- 
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ing, respectively (Fig. 1E, fourth and fifth panels) . To further confirm the specificity of DN-JNK, we examined lysates from DN-JNK transfected cells for both p38 MAPK and JNK activity using GST-ATF2 and GST-Jun as substrates, in an in vitro immune complex kinase assays. DN-JNK blocked 2ME2-induced JNK, but not p38MAPK activity (data not shown). Taken together, these results demonstrate that JNK is required for the release of Smac during 2ME2-induced apoptosis in MM cells. We next determined the functional significance of 2ME2-induced JNK activation. MM.1S cells were transiently transfected with either DN-JNK or empty vector and treated with 2ME2. As seen in Fig. 2A, after treatment (Fig. 2B) . As a control for specificity of a JNK inhibitor SP600125, we also treated cells with 2ME2 in the presence or absence of p38MAPK inhibitor. As seen in Fig. 2B , in contrast to SP600125, p38MAPK inhibitor does not attenuates 2ME2-induced cytotoxicity. Moreover, blockade of JNK also inhibits 2ME2-induced PARP cleavage, a signature event during apoptosis (Fig. 2C) . Other studies have reported that a decrease in mitochondrial membrane potential (⌬⌿ m ) causes release of Smac and cyto-c (5, 9), and we therefore asked whether 2ME2-induced apoptosis correlates with changes in ⌬⌿ m , and whether inhibition of JNK affects the ⌬⌿ m . As seen in Fig. 2D , 2ME2 triggers a significant decrease in ⌬⌿ m , and conversely, cotreatment with JNK inhibitor SP600125 prevents 2ME2-induced reduction in ⌿ m . Together, these data suggest that blockade of JNK decreased 2ME2-induced apoptosis. Our prior study demonstrated that 2ME2-induced apoptosis is associated with activation of caspase-8 and -9 (11), and both are known to activate downstream caspase-3 and PARP cleavage. In contrast to caspase-9, caspase-8-mediated apoptotic signaling may proceed independent of cyto-c or Smac release. It is likely, therefore, that the caspase-8 pathway may still be operative in response to 2ME2 despite the expression of DN-JNK, which may explain for the lack of complete protection provided by DN-JNK against 2ME2-induced apoptosis. Moreover, other upstream molecules besides JNK may modulate 2ME2-triggered Smac release, and further studies are required to understand these mechanisms.
Nevertheless our present findings demonstrate that JNK, at least in part, mediates 2ME2-induced apoptosis in MM cells.
To determine whether other apoptotic inducers in MM cells similarly affect the JNK-Smac signaling pathways, we treated MM.1S cells with a proteasome inhibitor PS-341 (10 nM) in the presence or absence of SP600125, and cell extracts were analyzed for both JNK activity and accumulation of Smac in the cytosol. PS-341 treatment of MM.1S cells triggers significant JNK activity, as well as release of Smac (Fig. 3, A and B, upper  panels) . Cotreatment with JNK inhibitor significantly blocks the PS-341-triggered release of Smac (Fig. 3, A and B, upper panels) , further confirming the requirement of JNK for release of Smac. Furthermore, similar results were obtained when patient MM (PCL) cells were exposed to 2ME2 (Fig. 3C) .
Exogenous JNK has been shown to phosphorylate many mitochondrial proteins during apoptosis (23); however, not all apoptotic agents trigger a sequential activation of JNK and mitochondrial pathways (25, 26) . Our prior studies showed that dexamethasone-induced apoptosis in MM.1S occurs independent of JNK activation, but is associated with Smac release (18) .
The observation that 2ME2 induces JNK activation in MM.1S cells suggest that JNK signaling is not defective in these cells. This is in concert with other studies demonstrating that antiFas-induced apoptosis is associated with the release of cyto-c in JNK-deficient mouse embryonic fibroblast cells, whereas UVinduced apoptosis in these same cells requires JNK activation for release of cyto-c (12) . These findings indicate that both activation of JNK and its requirement for the release of mitochondrial proteins are stimuli-specific.
Collectively, our present study shows that two distinct apoptotic agents in MM cells induce JNK, which upon activation translocates to mitochondria and triggers the release of Smac. Inhibition of JNK activation by either DN-JNK or a specific inhibitor of JNK disables JNK-mediated Smac release and associated apoptosis. Finally, our findings have important biologic and therapeutic implications. Given that synthetic Smac peptides enhance the apoptotic activity of chemotherapeutic agents (27) , coupled with our present results showing that anti-MM drugs induce apoptosis via release of mitochondrial Smac, suggest that Smac agonists or active Smac peptides may sensitize MM cells to 2ME2 or PS-341-induced cell death.
